Sarcoidosis-Associated Pulmonary Arterial Hypertension Treatment Guidelines

Initial Assessment and Diagnosis

The European Respiratory Society recommends confirming SAPH diagnosis with right heart catheterization, as echocardiography alone is insufficient for accurate diagnosis and treatment decisions 1

The European Respiratory Society and the American College of Chest Physicians recommend oxygen therapy to maintain arterial oxygen saturation >90% at all times, with continuous supplemental oxygen indicated when PaO2 is consistently <60 mmHg 1, 2
The American College of Chest Physicians suggests using diuretics for right ventricular failure with peripheral edema or ascites 1, 3
The American College of Chest Physicians recommends considering warfarin with target INR 1.5-2.5, though evidence is weaker in SAPH compared to idiopathic PAH 2
The European League Against Rheumatism suggests considering riociguat as alternative therapy, though data specific to sarcoidosis is limited 4
The American College of Chest Physicians recommends continuous intravenous epoprostenol as first-line therapy for WHO Functional Class IV patients, starting at 2 ng/kg/min and titrating by 1-2 ng/kg/min every 15 minutes until dose-limiting side effects occur 3

The European Respiratory Society recommends reassessing patients at 3-6 months with WHO functional class assessment, 6-minute walk distance, right heart catheterization, and brain natriuretic peptide (BNP) or NT-proBNP levels 1
The American Thoracic Society recommends treatment goals including improvement to WHO functional class I or II, 6-minute walk distance >440 meters, and reduction in pulmonary vascular resistance, although the specific 6-minute walk distance goal is from Praxis Medical Insights, a more general goal is recommended by other societies 5

The European Society of Cardiology recommends referring patients to a transplant center when they show inadequate response to maximal medical therapy, and considering double-lung or heart-lung transplantation for end-stage disease 6
The American College of Rheumatology suggests considering combination therapy with PDE-5 inhibitor plus endothelin receptor antagonist for inadequate response to bosentan monotherapy, and adding prostacyclin analogue for persistently high-risk patients 4, 3

Tadalafil may be used as an alternative first-line option at a dose of 40 mg daily orally, according to the Nature Reviews Rheumatology 7
Continuous intravenous epoprostenol is a first-line therapy for WHO Functional Class IV patients, starting at 2 ng/kg/min and titrating by 1-2 ng/kg/min every 15 minutes until dose-limiting side effects occur, as recommended by the Nature Reviews Rheumatology 7
Inhaled iloprost may be used as an alternative prostacyclin therapy at a dose of 2.5-5 μg per dose, 6-9 times daily, according to the Nature Reviews Rheumatology 7
Intravenous iloprost may be used as an alternative prostacyclin therapy at a dose of 0.5-2.0 ng/kg/min over 6 hours daily, as recommended by the Nature Reviews Rheumatology 7
Close monitoring of oxygen requirement is necessary, as patients may require increased supplemental oxygen after 16 weeks of treatment, highlighting the need for vigilance, according to the Nature Reviews Rheumatology 7